KEYNOTE-029 Results: Pembrolizumab + Low-Dose Ipilimumab in Metastatic Melanoma Patients

KEYNOTE-029 Results: Pembrolizumab + Low-Dose Ipilimumab in Metastatic Melanoma Patients

User Photo
AnnualMeeting2017

3 years
2,994 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC) and advanced melanoma: Phase 1 KEYNOTE-029 study
Up Next Autoplay
>